Anal HPV prevalence in individuals with and without other concomitant sexually transmitted infections.
Humans
Female
Prevalence
Adult
Male
Papillomavirus Infections
/ epidemiology
Middle Aged
Sexually Transmitted Diseases
/ epidemiology
Young Adult
Coinfection
/ epidemiology
Adolescent
Anal Canal
/ virology
Mycoplasma genitalium
/ isolation & purification
Papillomaviridae
/ isolation & purification
Aged
Chlamydia trachomatis
/ isolation & purification
Gonorrhea
/ epidemiology
Chlamydia Infections
/ epidemiology
Trichomonas vaginalis
/ isolation & purification
Mycoplasma Infections
/ epidemiology
Neisseria gonorrhoeae
/ isolation & purification
anus
chlamydia
gonorrhea
mycoplasma
papillomavirus
trichomoniasis
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
09
07
2024
received:
27
03
2024
accepted:
31
07
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
21
8
2024
Statut:
ppublish
Résumé
The association between human papillomavirus (HPV) and other sexually transmitted infections (STIs) in anal lesions still remains unclear. Aim of the study was to evaluate the prevalence of simultaneous infection of HPV and Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis in individuals screened for HPV anal infection. A total of 507 anal samples were tested for both anal HPV and STIs: 16% resulted positive for one or more non-HPV STIs. Specifically, C. trachomatis, M. genitalium, and N. gonorrhoeae were detected in 8%, 5%, and 4% of cases, respectively. Two groups were considered, including a positive STI group and a negative STI group. The prevalence of HPV was similar in patients in both groups: high risk (HR)-HPV and low risk (LR)-HPV were 67% and 53% versus 62% (p = 0.361) and 54% (p = 0.864) of patients, respectively. However, HPV 16, 18, 35, 51, 59, and 69 were significantly more frequent in patients tested positive for other STIs versus HPV infection alone (p < 0.05). No significant differences between the two groups were observed in vaccination coverage, 28% versus 32% (p = 0.463), and HIV status, 86% versus 84% (p = 0.658). The study shows that the overall HPV status is not directly correlated to other STIs in the investigated population, except for certain HPV types, including HR-HPV 16, reinforcing the urge for a greater vaccination coverage.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29852Informations de copyright
© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.
Références
Genital HPV Infection—Basic Fact Sheet. Centers for Disease Control and Prevention, CDC. Accessed July 5, 2024. https://www.cdc.gov/std/hpv/stdfact-hpv.htm
Van Gerwen OT, Muzny CA, Marrazzo JM. Sexually transmitted infections and female reproductive health. Nat Microbiol. 2022;7(8):1116‐1126. doi:10.1038/s41564-022-01177-x
World Health Organization. Sexually Transmitted Infections (STIs). Key facts. July 2023. Accessed October 17, 2023. https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
Bruni L, Albero G, Rowley J, et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta‐analysis. Lancet Global Health. 2023;11(9):e1345‐e1362. doi:10.1016/S2214-109X(23)00305-4
Dunne EF, Park IU. HPV and HPV‐associated diseases. Infect Dis Clin North Am. 2013;27(4):765‐778. doi:10.1016/j.idc.2013.09.001
World Health Organization. Human papillomavirus vaccines (HPV). Immunization, Vaccines and Biologicals. December 2022. Accessed January 11, 2024. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-(HPV)
Chesson HW, Mayaud P, Aral SO. Sexually transmitted infections: Impact and cost‐effectiveness of prevention. In: Holmes KK, Bertozzi S, Bloom BR, et al. editors. Major Infectious Diseases, 3rd ed. The International Bank for Reconstruction and Development/The World Bank; 2017. November 3, Chapter 10. Available from https://www.ncbi.nlm.nih.gov/books/NBK525195/. doi:10.1596/978-1-4648-0524-0_ch10
Alotaibi HJ, Almajhdi FN, Alsaleh AN, et al. Association of sexually transmitted infections and human papillomavirus co‐infection with abnormal cervical cytology among women in Saudi Arabia. Saudi J Biol Sci. 2020;27(6):1587‐1595. doi:10.1016/j.sjbs.2020.03.021
Lu Z, Zhao P, Lu H, Xiao M. Analyses of human papillomavirus, Chlamydia trachomatis, Ureaplasma urealyticum, Neisseria gonorrhoeae, and co‐infections in a gynecology outpatient clinic in Haikou area, China. BMC Womens Health. 2023;23(1):117. doi:10.1186/s12905-023-02259-6
de Abreu AL, Malaguti N, Souza RP, et al. Association of human papillomavirus, Neisseria gonorrhoeae and Chlamydia trachomatis co‐infections on the risk of high‐grade squamous intraepithelial cervical lesion. Am J Cancer Res. 2016;6(6):1371‐1383.
Ye H, Song T, Zeng X, Li L, Hou M, Xi M. Association between genital mycoplasmas infection and human papillomavirus infection, abnormal cervical cytopathology, and cervical cancer: a systematic review and meta‐analysis. Arch Gynecol Obstet. 2018;297(6):1377‐1387. doi:10.1007/s00404-018-4733-5
Masiá M, Fernández‐González M, García JA, et al. Infection with Chlamydia trachomatis increases the risk of high‐grade anal intraepithelial neoplasia in people living with human immunodeficiency virus. Clin Infect Dis. 2020;70(10):2161‐2167. doi:10.1093/cid/ciz606
Rizzo A, Moschese D, Salari F, et al. High prevalence of high‐risk HPV genotypes in individuals attending an infectious diseases clinic from 2018 to 2022 in Milan, Italy. J Med Virol. 2024;96(1):e29370. doi:10.1002/jmv.29370
Centers for Disease Control and Prevention. Men Who Have Sex with Men (MSM). Sexually Transmitted Infections Treatment Guidelines, 2021. Accessed July 2021. https://www.cdc.gov/std/treatment-guidelines/msm.htm
Tu W, Li YY, Kuang YQ, et al. High prevalence of sexually transmitted infections and risk factors among HIV‐positive individuals in Yunnan, China. Eur J Med Res. 2022;27(1):9. doi:10.1186/s40001-022-00635-w
Jansen K, Steffen G, Potthoff A, et al. STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. BMC Infect Dis. 2020;20(1):110. doi:10.1186/s12879-020-4831-4
Wei F, Gaisa MM, D'Souza G, et al. Epidemiology of anal human papillomavirus infection and high‐grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV. 2021;8(9):e531‐e543. doi:10.1016/S2352-3018(21)00108-9
Fasciana T, Capra G, Di Carlo P, et al. Socio‐demographic characteristics and sexual behavioral factors of patients with sexually transmitted infections attending a hospital in Southern Italy. Int J Environ Res Public Health. 2021;18(9):4722. doi:10.3390/ijerph18094722
Muresu N, Sotgiu G, Saderi L, et al. Distribution of HPV genotypes in patients with a diagnosis of anal cancer in an Italian region. Int J Environ Res Public Health. 2020;17(12):4516. doi:10.3390/ijerph17124516
Chinyowa S, Palefsky JM, Chirenje ZM, Makunike‐Mutasa R, Munjoma M, Muguti GI. Anal human papillomavirus infection in HIV‐positive men and women at two opportunistic infections clinics in Harare, Zimbabwe. BMC Public Health. 2018;18(1):1260. doi:10.1186/s12889-018-6170-6
Paula Almeida Cunha A, Kassandra Pereira Belfort I, Pedro Belfort Mendes F, et al. Human papillomavirus and its association with other sexually transmitted coinfection among sexually active women from the northeast of Brazil. Interdiscip Perspect Infect Dis. 2020;2020:8838317. doi:10.1155/2020/8838317
Biernat‐Sudolska M, Szostek S, Rojek‐Zakrzewska D, Klimek M, Kosz‐Vnenchak M. Concomitant infections with human papillomavirus and various mycoplasma and ureaplasma species in women with abnormal cervical cytology. Adv Med Sci. 2011;56(2):299‐303. doi:10.2478/v10039-011-0028-9
Discacciati MG, Gimenes F, Pennacchi PC, et al. MMP‐9/RECK imbalance: a mechanism associated with high‐grade cervical lesions and genital infection by human papillomavirus and Chlamydia trachomatis. Cancer Epidemiol Biomarkers Prevent. 2015;24(10):1539‐1547. doi:10.1158/1055-9965.EPI-15-0420
Jiang M, Ding H, He L, et al. Association between co‐infection with Chlamydia trachomatis or Mycoplasma genitalium and cervical lesions in HPV‐positive population in Hunan, China: a cross‐sectional study. Infect Agent Cancer. 2023;18(1):76. doi:10.1186/s13027-023-00544-5
Ma Z, Gharizadeh B, Cai X, et al. A comprehensive HPV‐STI NGS assay for detection of 29 HPV types and 14 non‐HPV sexually transmitted infections. Infect Agent Cancer. 2022;17(1):9. doi:10.1186/s13027-022-00420-8
Nikolic N, Basica B, Mandic A, et al. E6/E7 mRNA expression of the most prevalent high‐risk HPV genotypes in cervical samples from serbian women. Diagnostics. 2023;13(5):917. doi:10.3390/diagnostics13050917
Olivera C, Mosmann JP, Anna AN, et al. Expression of HPV‐16 E6 and E7 oncoproteins alters Chlamydia trachomatis developmental cycle and induces increased levels of immune regulatory molecules. Front Cell Infect Microbiol. 2023;13:1214017. doi:10.3389/fcimb.2023.1214017
Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337(19):1350‐1358. doi:10.1056/NEJM199711063371904
Jalil EM, Wilson EC, Monteiro L, et al. High prevalence of anal high‐risk HPV infection among transwomen: estimates from a Brazilian RDS study. J Int AIDS Soc. 2021;24(3):e25691. doi:10.1002/jia2.25691
Chambers C, Deeks SL, Sutradhar R, et al. Vaccine effectiveness against 12‐month incident and persistent anal human papillomavirus infection among gay, bisexual, and other men who have sex with men. J Infect Dis. 2023;228(1):89‐100. doi:10.1093/infdis/jiad005
Erratum: J Infect Dis. 2023;227(10):1219.
Pan American Health Organization. Human Papillomavirus (HPV) Vaccine. World Health Organization. Accessed March 18, 2024. https://www.paho.org/en/human-papillomavirus-hpv-vaccine
Rosado C, Fernandes ÂR, Rodrigues AG, Lisboa C. Impact of human papillomavirus vaccination on male disease: a systematic review. Vaccines. 2023;11(6):1083. doi:10.3390/vaccines11061083